HTL0048149 / Nxera Pharma - LARVOL DELTA

Orphan GPR52 as an emerging neurotherapeutic target. (PubMed, Drug Discov Today) - "Excitingly, HTL0048149 (HTL'149), an orally available GPR52 agonist, has been advanced into phase I human clinical trials for the treatment of schizophrenia...The opportunities and challenges presented by targeting GPR52 for novel therapeutics are also briefly discussed. Teaser Targeting the G protein-coupled receptor GPR52 offers a novel and emerging neurotherapeutic approach for the treatment of schizophrenia, Huntington's disease, cognitive impairment, psychotic disorders and psychostimulant disorders."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Huntington's Disease • Mental Retardation • Movement Disorders • Psychiatry • Schizophrenia • GPR52

Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia (GlobeNewswire) - "Sosei Group Corporation...announces it has dosed the first subject in a Phase I trial evaluating HTL0048149 (HTL’149), a first-in-class GPR52 agonist, which represents a novel mechanism of action for the treatment of schizophrenia and related neurological diseases....The Phase I trial is a two-part, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study to assess the safety, pharmacokinetics, and pharmacodynamics of oral HTL’149 in healthy volunteers aged 18-55 years. The trial will be conducted in the UK and is expected to read-out initial data in 12-18 months."

Trial status • CNS Disorders • Schizophrenia